Advertisement FDA Approves Beech Tree Labs' Recurrent Oral Herpes Infections IND Application - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More

Norwich Clinical Research Associates

Clinical Monitoring, Auditing, and Data Management Services

FDA Approves Beech Tree Labs’ Recurrent Oral Herpes Infections IND Application

According to WHO and CDC statistics, over 80% of the population have oral herpes with about 20% of these expressing symptoms. One of four adults has genital herpes, with the incidence steadily increasing.

Herpes simplex, the virus causing oral herpes, serves as the prototype of a Beech Tree Labs’ approach that potentially addresses a broad spectrum of herpes virus indications. The active agent is also embodied in a product candidate that recently received FDA approval of an IND targeting influenza, presenting evidence of a growing Beech Tree anti-viral platform.

Beech Tree Labs is a privately held biopharmaceutical company specialising in discovery and early-stage development through phase two clinical trials, followed by licensing to larger pharmaceutical and biotech firms for late-stage evaluation and marketing. It is a leader in resonant molecular signaling technology and holds a number of patents on other potential therapeutics.

Quick Contact